| Date | Title | Description |
| 30.06.2025 | HBM Healthcare Investments AG completes share buyback programme | On 27 June 2025, HBM Healthcare Investments AG concluded its 2022 share buyback programme, which was initiated in June 2022. A total of 252,610 shares of HBM Healthcare Investments AG were repurchased via a separate trading line on the SIX ... |
| 15.05.2025 | Ad hoc announcement pursuant to Art. 53 LR2024/2025 financial year: HBM Healthcare achieved profit of CHF 19 million in a challenging environment |
HBM Healthcare Investments generated an annual profit of CHF 19 million in the 2024/2025 financial year in a challenging environment. The net asset value per share (NAV) rose by 1.5 percent, while the share price declined slightly by –2.6 ... |
| 01.04.2025 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments expects to report a net profit of CHF 19 million for the 2024/2025 financial year | In a market environment that remains difficult for the biotech sector, HBM Healthcare Investments closed the 2024/2025 financial year with a net profit of CHF 19 million as of 31 March. Net asset value per share (NAV) rose by 1.5 percent to... |
| 20.03.2025 | Ad hoc announcement pursuant to Art. 53 LRSanofi to acquire DR-0201, a clinical-stage program of HBM portfolio company Dren Bio, for upfront amount of USD 600 million, plus potential milestones | HBM Healthcare Investments (SIX: HBMN) today announced that Dren Bio, a private portfolio company, and Sanofi have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell enga... |
| 20.01.2025 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Quarterly Report as at 31 December 2024 with key figures for the first nine months of the 2024/2025 financial year |
Positive result for the first nine months ended 31 December 2024
HBM Healthcare Investments generated a profit of CHF 66 million in the first nine months of the 2024/2025 financial year ended 31 December 2024.
The performance in the first ... |
| 03.01.2025 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments reports a compelling 15 percent increase in NAV in the 2024 calendar year | HBM Healthcare Investments closed the calendar year 2024 with a strong performance. Its net asset value (NAV) per share rose by 15 percent to CHF 251.17. By contrast, the share price failed to reflect this good performance, growing only mar... |
| 18.12.2024 | Ad hoc announcement pursuant to Art. 53 LRSuccessful IPO of HBM portfolio company Sai Life Sciences on the Indian stock exchanges NSE and BSE increases NAV per HBM share by 3.2 percent | Sai Life Sciences (NSE/BSE: SAILIFE), a portfolio company of HBM Healthcare Investments, made a successful debut on the Indian stock exchanges NSE and BSE today. The company raised new capital of INR 9.5 billion (CHF 100 million) by issuing... |
| 21.10.2024 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Half-Year Report as at 30 September 2024 with key figures for the first six months of the 2024/2025 financial year |
Successful first half – currency effects impact performance
HBM Healthcare Investments generated a profit of CHF 23 million for the first six months of the 2024/2025 financial year ended 30 September 2024. Net asset value per share (NAV) r... |
| 14.10.2024 | HBM portfolio company Upstream Bio raises USD 255 million in successful initial public offering | Upstream Bio (Nasdaq: UPB), a previously private company in the HBM Healthcare Investments portfolio, got off to a successful start on the stock market last Friday. The company raised USD 255 million in new capital through the issuance of 1... |
| 01.10.2024 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments posts half-year profit of CHF 23 million for 2024/2025 financial year; currency effects had a strong negative impact on the result | HBM Healthcare Investments achieved a positive performance in the first half of the 2024/2025 financial year. The net asset value per share (NAV) increased by 1.5 per cent to CHF 244.34. The share price rose by 1.7 per cent to CHF 189.40.
B... |
| 19.07.2024 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Quarterly Report as at 30 June 2024 with key figures for the first three months of the 2024/2025 financial year |
Positive start to the new financial year
HBM Healthcare Investments started the new 2024/2025 financial year with a quarterly profit of CHF 26 million. The net asset value per share (NAV) rose by 1.6 percent in the first three months to 30... |
| 28.05.2024 | Ad hoc announcement pursuant to Art. 53 LRHBM portfolio company Yellow Jersey Therapeutics to be acquired for USD 1.25 billion | HBM Healthcare Investments (SIX: HBMN) today announced that Yellow Jersey Therapeutics, a portfolio company, has entered into an agreement with Johson & Johnson, whereby Johnson & Johnson will acquire global rights to NM26, a Phase ... |
| 22.05.2024 | HBM Healthcare Investments' portfolio company Swixx BioPharma boosts sales and profits through strategic acquisition in Latin America | Swixx BioPharma, the largest investment in the private equity portfolio of HBM Healthcare Investments, today announced its strategic expansion into Latin America with the signing of an agreement to acquire the Laboratorios Biopas Group.
The... |
| 08.05.2024 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments achieves a balanced result in the 2023/2024 financial year |
HBM Healthcare Investments almost broke even in the 2023/2024 financial year with a slight loss of CHF 1 million. The net asset value per share (NAV) rose by 0.3 percent as the number of shares outstanding was reduced by share buy-backs. T... |
| 02.04.2024 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes net asset value per share (NAV) of CHF 248.10 as at 31 March 2024 and quarterly profit of CHF 156 million | HBM Healthcare Investments generated a profit of CHF 156 million in the final quarter of the 2023/24 financial year as at the end of March. This largely made up for the loss from the first nine months. The net asset value per share (NAV) ro... |
| 22.01.2024 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Quarterly Report as at 31 December 2023 with key figures for the first nine months of the 2023/2024 financial year | Unfavourable currency developments drag HBM Healthcare into the red |
| 03.01.2024 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes net asset value per share (NAV) of CHF 225.03 as at 31 December 2023 | HBM Healthcare Investments closed the 2023 calendar year with a negative performance due to unfavourable currency developments. The net asset value per share (NAV) fell by 8.3 percent to CHF 225.03. The share price declined by 5.4 percent t... |
| 30.11.2023 | AbbVie to acquire HBM portfolio company ImmunoGen for USD 10.1 billion in cash | HBM Healthcare Investments today announced that its portfolio company ImmunoGen (NASDAQ: IMGN) will be acquired by AbbVie (NYSE: ABBV) for USD 10.1 billion in cash. The acquisition price of USD 31.26 per ImmunoGen share represents a premium... |
| 16.10.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Half-Year Report as at 30 September 2023 with key figures for the second quarter of the 2023/2024 financial year | |
| 16.10.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments activates share buyback programme | The discount of the share price to the reported net asset value per share (NAV) has widened in recent days to an extent that the Board of Directors and the Management of HBM Healthcare Investments are convinced does not reflect the fundamen... |
| 02.10.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Net Asset Value per Share (NAV) of CHF 237.22 as at 30 September 2023 | The net asset value per share (NAV) fell by 4.0 per cent to CHF 237.22 in the first six months of the 2023/2024 financial year. The performance thus is in line with the performance of the biotechnology sector as measured by the Nasdaq Biote... |
| 21.07.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes interim report for the quarter ended 30 June 2023 with key figures for the first three months of the 2023/2024 financial ... | Unfavourable currency developments push quarterly result into the red |
| 26.06.2023 | Ad hoc announcement pursuant to Art. 53 LRCathay Biotech raises capital and enters into major strategic collaboration with China Merchants Group | Cathay Biotech, the largest holding in HBM Healthcare Investments' portfolio (15% of net assets), yesterday announced a significant strategic collaboration with China Merchants Group (CMG). The transaction, which is subject to approval by C... |
| 26.05.2023 | Ad hoc announcement pursuant to Art. 53 LRPublication of Annual Report 2022/2023 and Invitation to the Ordinary Shareholders’ Meeting | The invitation to the 22nd Ordinary Shareholders’ Meeting on 19 June 2023 has been sent to the shareholders of HBM Healthcare Investments today. |
| 12.05.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments year-end results 2022/2023 | HBM Healthcare Investments reports a loss of CHF 146 million for the 2022/2023 financial year. Inflation and rising interest rates led to declining valuations for technology and growth stocks around the globe. Four profitable acquisitions, ... |
| 03.04.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes net asset value per share of CHF 254.80 as at 31 March 2023 | HBM Healthcare Investments closed the fourth quarter of the 2022/2023 financial year ended on 31 March with a small increase in value. The net asset value per share (NAV) increased by 0.5 percent to CHF 254.80. The share price rose by 6.5 p... |
| 28.03.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments announces the return of Dr Andreas Wicki; new investment of USD 12 million in ArriVent Biopharma | HBM Healthcare Investments refers to its media release dated 30 January 2023. Dr Andreas Wicki has recovered from his health matters and will fully resume his duties as Chief Executive Officer of HBM Healthcare Investments and with the inve... |
| 13.02.2023 | Successful IPO of HBM portfolio company Mineralys Therapeutics | Mineralys Therapeutics (Nasdaq: MLYS), a previously private company in the portfolio of HBM Healthcare Investments, successfully completed its IPO last Friday. The company placed 12 million new shares at a price of USD 16.00 per share, rais... |
| 30.01.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments informs about a temporary change in the Executive Board | Dr Andreas Wicki, Chief Executive Officer of HBM Healthcare Investments, will be taking a brief leave of absence to adress a treatable health matter. Dr Wicki will remain involved to the extent practicable. |
| 20.01.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Quarterly Report with key figures for the quarter ended 31 December 2022 and for the first nine months of the 2022/2023 f... | |
| 03.01.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes net asset value per share of CHF 253.59 as at 31 December 2022 | HBM Healthcare Investments suffered a negative performance for the calendar year 2022 in a declining market. The net asset value per share (NAV) declined by 21.7 percent to CHF 253.59. The share price fell by a much greater 37.8 percent to ... |
| 21.10.2022 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments Half-Year Report September 2022 | HBM Healthcare Investments recorded a decrease in value of CHF 86 million in the second quarter of the 2022/2023 financial year ended 30 September. The net asset value per share (NAV) declined by 4.2 percent. For the first half of the finan... |
| 03.10.2022 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Net Asset Value per Share (NAV) of CHF 270.92 as at 30 September 2022 | The net asset value per share (NAV) as at 30 September 2022 amounts to CHF 270.92 and is thus 1.7 percent lower than at the beginning of the current financial year 2022/23. In comparison, the MSCI World Health Care Sector Index declined by ... |
| 22.07.2022 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments Quarterly Report June 2022 | HBM Healthcare Investments achieved a net profit of CHF 52 million in the first quarter of the 2022/2023 financial year in an overall declining market environment. The net asset value per share rose by 2.6 percent, while the share price fel... |
| 28.06.2022 | HBM Healthcare Investments Ltd concludes 2019 share buyback programme and launches new share buyback programme | Yesterday, HBM Healthcare Investments Ltd concluded the 2019 share buyback programme that started in June 2019. Under the buyback programme, no registered shares were repurchased via the second trading line on the SIX Swiss Exchange. |
| 10.06.2022 | Shareholders’ Meeting of HBM Healthcare Investments approved all proposals by the Board of Directors | At today’s ordinary Shareholders’ Meeting of HBM Healthcare Investments Ltd the shareholders approved all proposals submitted by the Board of Directors. Based on the Federal Council's COVID 19 Ordinance 3, the meeting was held without the p... |
| 03.06.2022 | Bristol Myers Squibb to Acquire HBM Portfolio Company Turning Point Therapeutics for USD 4.1 billion in cash | HBM Healthcare Investments today announces that its portfolio company Turning Point Therapeutics (NASDAQ: TPTX) will be acquired by Bristol Myers Squibb (NYSE: BMY) in an all-cash transaction that values the company at USD 4.1 billion. The ... |
| 18.05.2022 | Ad hoc announcement pursuant to Art. 53 Listing RulesPublication of Annual Report 2021/2022 and Invitation to the Ordinary Shareholders’ Meeting | The invitation to the 21st Ordinary Shareholders’ Meeting on 10 June 2022 has been sent to the shareholders of HBM Healthcare Investments today. |
| 10.05.2022 | Pfizer to acquire HBM portfolio company Biohaven Pharmaceuticals in USD 11.6 billion deal | HBM Healthcare Investments today announces that its portfolio company Biohaven Pharmaceuticals (NYSE: BHVN) will be acquired by Pfizer (NYSE: PFE) for USD 11.6 billion in cash. The acquisition price of USD 148.50 per Biohaven share represen... |
| 06.05.2022 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments year-end results 2021/2022 | HBM Healthcare Investments reports a loss of CHF 78 million for the 2021/2022 financial year, for the first time in ten years and after a cumulative increase in value of 550 percent. The net asset value per share (NAV) fell by 3.6 percent a... |
| 01.04.2022 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments publishes Net Asset Value per Share (NAV) of CHF 285.53 as of 31 March 2022 | Following the previous year's record result, HBM Healthcare Investments experienced a slight decline in value in the 2021/22 financial year ended on 31 March 2022. The net asset value (NAV) per share fell by 3.6 percent to CHF 285.53. The s... |
| 21.01.2022 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments Quarterly Report December 2021 | HBM Healthcare Investments generated a net profit of CHF 4 million in the reporting quarter ended 31 December 2021. For the first nine months of the 2021/2022 financial year, the net profit amounts to CHF 275 million. Although the biotech s... |
| 03.01.2022 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments delivers strong return despite weak biotech sector and increases net asset value per share (NAV) by 19 percent in calend... | HBM Healthcare Investments closes the 2021 calendar year with another strong performance. The net asset value per share (NAV) rose by 19 percent to CHF 336.27 as at 31 December 2021, while the share price increased by 15.2 percent to close ... |
| 08.11.2021 | HBM Healthcare Investments benefits from the IPO of portfolio company IO Biotech | IO Biotech (Nasdaq: IOBT), a so far privately held company in the HBM Healthcare Investments portfolio, issued 7.15 million new shares at a price of USD 14.00 per share in last Friday's IPO on the US Nasdaq, raising USD 100 million in new c... |
| 22.10.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments Half-year Report September 2021 | HBM Healthcare Investments generated for the first half of the financial year from 1 April to 30 September 2021, a profit of CHF 271 million while NAV increased by 12.6 percent to CHF 335.64. The share price rose 6.0 percent to CHF 340.00. |
| 01.10.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments achieves value growth of 12.6 percent in the first half of the 2021/2022 financial year | HBM Healthcare Investments' net assets continued to grow in the first half of the 2021/2022 financial year, thanks to the excellent performance of the listed investment in Cathay Biotech in China and contributions from the private companies... |
| 23.07.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments Quarterly Report June 2021 | HBM Healthcare Investments closed the first quarter of the 2021/2022 financial year with a profit of CHF 136 million. The increase in the net asset value per share (NAV) amounted to 6.3 percent. The share price rose by 6.9 percent. The inve... |
| 25.06.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesSuccessful IPO for HBM portfolio company Monte Rosa Therapeutics | Monte Rosa Therapeutics (Nasdaq: GLUE), a private company in the portfolio of HBM Healthcare Investments, reached an important milestone in the company's development with yesterday's successful IPO on Nasdaq. By issuing 11.7 million shares ... |
| 21.06.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM portfolio company Ambrx Biopharma raises USD 126 million in initial public offering on New York Stock Exchange | Ambrx Biopharma (NYSE: AMAM), a private company in the portfolio of HBM Healthcare Investments, completed its initial public offering on the New York Stock Exchange last Friday. The company raised USD 126 million in new capital through the ... |
| 16.06.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments has ended the subscription period for the bond early and increased the issue amount to CHF 100 million | HBM Healthcare Investments AG successfully completed the placement of the bond early, with Helvetische Bank AG and Raiffeisen Schweiz Cooperative acting as Joint-Lead Managers. Due to the strong demand, the coupon was fixed at the lower end... |
| 15.06.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments Ltd announces the issue of a bond with a 6-year term and a minimum issue amount of CHF 60 million | HBM Healthcare Investments Ltd announces the issue of a bond with a 6-year term and a nominal amount of CHF 60 million with the possibility to increase the issue amount up to a maximum of CHF 75 million. The proceeds will be used to refinan... |
| 10.06.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesTata Digital to acquire majority stake in HBM portfolio company 1mg, India’s leading digital healthcare platform | HBM Healthcare Investments announced today, that Tata Digital, a fully-owned subsidiary of Tata Sons Private Limited, to acquire a majority stake of its privately held portfolio company 1mg. |
| 09.06.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM portfolio company Valo Health and Khosla Ventures Acquisition Co. to combine and create publicly traded company | HBM Healthcare Investments announced today that its portfolio company Valo Health (“Valo”), a technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development p... |
| 28.05.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM portfolio company Swixx BioPharma announces EUR 45 million capital increase | Swixx BioPharma, a privately held company in the portfolio of HBM Healthcare Investments, today announced the signing of an investment agreement with Mérieux Equity Partners and its existing shareholders. Under the terms of the agreement, M... |
| 27.05.2021 | Invitation to the 20th Ordinary Shareholders' Meeting | Friday, 18 June 2021, 4.45 pm at the Company's registered office in Zug |
| 27.05.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesPublication of Annual Report 2020/2021 and Invitation to the Ordinary Shareholders’ Meeting | The invitation to the 20th Ordinary Shareholders’ Meeting on 18 June 2021 has been sent to the shareholders of HBM Healthcare Investments today. |
| 07.05.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesChanges to the Board of Directors of HBM Healthcare Investments Ltd | Board of Directors of HBM Healthcare Investments Ltd proposes Dr Elaine V. Jones, an experienced and well connected executive, to be elected to the Board of Directors at the Shareholders' Meeting on 18 June 2021. In this regard, the Company... |
| 07.05.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments reports a profit of CHF 756 million for the 2020/2021 financial year; Increase of the proposed cash distribution to a to... | In the 2020/2021 financial year, HBM Healthcare Investments recorded a profit of CHF 756 million, the highest since it was founded 20 years ago. The net asset value (NAV) rose by more than half (+52 percent) in the reporting year and the HB... |
| 01.04.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments closes anniversary year with record profit of over CHF 750 million | HBM Healthcare Investments will close its 20th financial year, ending on 31 March 2021, with a record result. The net asset value per share (NAV) rose by 52 percent to CHF 309.25. The share price climbed disproportionately by 79 percent to ... |
| 22.03.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesIPOs of Instil Bio and Connect Biopharma increase net asset value per HBM share by CHF 4.55 (+1.5%) | With Instil Bio (Nasdaq: TIL) and Connect Biopharma (Nasdaq: CNTB), two more private companies from the HBM Healthcare Investments portfolio successfully went public last Friday. |
| 15.03.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesSuccessful debut on the stock exchange for HBM portfolio company Longboard Pharmaceuticals | Longboard Pharmaceuticals (Nasdaq: LBPH), a private company in the portfolio of HBM Healthcare Investments, completed its IPO last Friday. The company raised USD 80 million in new capital by issuing 5 million shares at a price of USD 16.00 ... |
| 01.02.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHorizon Therapeutics to acquire HBM portfolio company Viela Bio for USD 3.05 billion in cash | Horizon Therapeutics (Nasdaq: HZNP) and Viela Bio (Nasdaq: VIE) today announced that the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and outstanding shares of Viela Bio for USD 53.00... |
| 22.01.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments Quarterly Report December 2020 | HBM Healthcare Investments continued its impressive growth in net assets in the third quarter of the 2020/2021 financial year. Thanks to a quarterly profit of CHF 203 million with contributions from all portfolio categories, the result for ... |
| 04.01.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments proves resilient: net asset value per share (NAV) up 36.7 percent in calendar year 2020, share price up 40.5 percent | HBM Healthcare Investments closed the volatile 2020 calendar year, marked by the uncertainties surrounding the Covid-19 pandemic, with an outstanding result. Net asset value per share (NAV) rose by a high 36.7 percent to CHF 293.21 as at 31... |
| 17.12.2020 | Ad hoc announcement pursuant to Art. 53 Listing RulesIPOs of Bioatla and Seer boost HBM Healthcare Investments’ net asset value per share | With Bioatla (Nasdaq: BCAB), another private company from the HBM Healthcare Investments portfolio successfully went public yesterday. The company placed 10.5 million new shares at USD 18.00, raising USD 189 million. On yesterday's first tr... |
| 02.11.2020 | HBM Healthcare Investments nominates Dr Elaine Jones for the election to the Board of Directors | The Board of Directors of HBM Healthcare Investments AG is nominating Dr Elaine Jones for the election to the Board of Directors at the Annual General Meeting on 18 June 2021. Dr Jones is an experienced biopharmaceutical executive with more... |
| 30.10.2020 | HBM-backed Galecto raises USD 85 million in Nasdaq IPO | Galecto (Nasdaq: GLTO), a privately held company in the portfolio of HBM Healthcare Investments, completed its intended IPO. The company placed 5.67 million new shares at a price of USD 15.00 per share, raising USD 85 million in new capital... |
| 28.10.2020 | HBM Healthcare Investments sells stake in Westmed Holding Company | HBM Healthcare Investments today announces that the shareholders of Westmed Holding Company («Westmed»), a privately held portfolio company based in Colorado, USA, have approved a merger of Westmed with a subsidiary of Sunmed Group Holdings... |
| 23.10.2020 | HBM Healthcare Investments Half-year Report September 2020 | HBM Healthcare Investments maintained its strong performance in the second quarter of the 2020/2021 financial year, with four IPOs and three takeovers making a substantial contribution to its quarterly profit of CHF 215 million. This took t... |
| 09.10.2020 | Successful IPO of Everest Medicines on the Hong Kong Stock Exchange | Everest Medicines (symbol: 1952 HK), a privately held company in the portfolio of HBM Healthcare Investments, today completed its announced initial public offering on the Hong Kong Stock Exchange. The company raised HKD 3.5 billion (CHF 413... |
| 05.10.2020 | HBM portfolio company C4 Therapeutics raises USD 182 million in initial public offering; marginal positive impact on NAV per HBM share | C4 Therapeutics (Nasdaq: CCCC), a private company in the portfolio of HBM Healthcare Investments, completed its planned IPO last Friday. The company raised USD 182 million in new capital by issuing 9.6 million shares at a price of USD 19.00... |
| 01.10.2020 | HBM Healthcare Investments expects net profit of around CHF 441 million for first half of financial year 2020/2021 | The net asset value per HBM share (NAV) increased by 30.5 percent to CHF 263.98 in the first six months of the financial year 2020/2021 ending on 31 March. The share price rose by 46.2 percent to CHF 270.00. The four IPO's of Cathay Biotech... |
| 14.09.2020 | Gilead Sciences to acquire HBM portfolio company Immunomedics | Gilead Sciences (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU), a listed portfolio company of HBM Healthcare Investments, announced yesterday that the companies have entered into a definitive agreement pursuant to which Gilead will acquire ... |
| 24.08.2020 | Bristol Myers Squibb acquires HBM portfolio company Forbius | Bristol Myers Squibb (NYSE: BMY) and Forbius, a privately held company in the portfolio of HBM Healthcare Investments, today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will acquire Forbius.... |
| 20.08.2020 | Successful IPO for Harmony Biosciences; Net asset value per HBM share increases by CHF 14.74 (+5.5%) | The announced IPO of Harmony Biosciences Holdings (Nasdaq: HRMY), a so far privately held company in the portfolio of HBM Healthcare Investments, was successfully completed. The company placed 5.35 million new shares at a price of USD 24.00... |
| 12.08.2020 | HBM Healthcare Investments benefits strongly from the IPO of Cathay Biotech; Net asset value per HBM share increases by CHF 32.20 (+13.7%); Cathay stake grows to 24 percent of net assets | The initial public offering of Cathay Biotech (Chinese name: 上海凯赛生物技术股份有限公司) (SSE STAR Market: 688065), a so far privately held company in the portfolio of HBM Healthcare Investments, on the Chinese technology exchange in Shanghai ("SS... |
| 11.08.2020 | HBM portfolio company Harmony Biosciences announces details of its IPO | Harmony Biosciences Holdings, a private company in the portfolio of HBM Healthcare Investments, today announced the details of its planned IPO on the Nasdaq stock exchange. The company intends to issue 4.65 million new shares at a price of ... |
| 31.07.2020 | HBM Healthcare Investments informs about the IPO of Cathay Biotech; Positive impact on the net asset value per HBM share (NAV) expected | Cathay Biotech (Chinese name: 上海凯赛生物技术股份有限公司) (SSE STAR Market: 688065), a so far privately held company in the portfolio of HBM Healthcare Investments, today announced details of its initial public offering on the Chinese technology exchan... |
| 27.07.2020 | HBM portfolio company iTeos Therapeutics raises USD 201 million in initial public offering; marginal positive impact on NAV per HBM-share | iTeos Therapeutics (Nasdaq: ITOS), a private company in the portfolio of HBM Healthcare Investments, completed its planned IPO last Friday. The company raised USD 201 million in new capital by issuing 10.6 million shares at a price of USD 1... |
| 24.07.2020 | HBM Healthcare Investments Quarterly Report June 2020 | HBM Healthcare Investments looks back on a successful first quarter of the 2020/2021 financial year. The significant market recovery, positive corporate news and two acquisitions resulted in a net profit of CHF 226 million for the first thr... |
| 20.07.2020 | ALX Oncology's IPO positively impacts the net asset value per HBM share | ALX Oncology (Nasdaq: ALXO), a privately held company in the portfolio of HBM Healthcare Investments, successfully went public. The company placed 8.5million new shares at a price of USD 19.00 per share, raising a total of USD 161.5 million... |
| 01.07.2020 | Key Figures / Kennzahlen | |
| 11.06.2020 | Novo Nordisk acquires HBM portfolio company Corvidia Therapeutics for up to USD 2.1 billion in cash | Novo Nordisk (NYSE: NVO) today announced that it has entered into a definitive agreement to acquire Corvidia Therapeutics, a privately held company in the portfolio of HBM Healthcare Investments. |
| 26.05.2020 | Publication of Annual Report 2019/2020 and Invitation to the Ordinary Shareholders' Meeting | The invitation to the 19th Ordinary Shareholders' Meeting on 22 June 2020 has been sent to the shareholders of HBM Healthcare Investments today. |
| 26.05.2020 | Invitation to the 19th Ordinary Shareholders' Meeting | Monday, 22 June 2020, 4:45 pm at the Company's registered office in Zug |
| 08.05.2020 | HBM Healthcare Investments nominates Dr Stella X. Xu for the Board of Directors | The Board of Directors of HBM Healthcare Investments AG proposes Dr Stella X. Xu for the election to the Board of Directors. Dr Xu is a proven expert in investing in innovative healthcare companies, with in-depth knowledge of the pharmaceut... |
| 08.05.2020 | HBM Healthcare Investments reports a profit of CHF 183 million for the 2019/2020 financial year; Increase of the proposed cash distribution to CHF 7.70 per share. | In the financial year 2019/2020, HBM Healthcare Investments achieved consistently high value creation, with profit of CHF 183 million and a 14 percent increase in net asset value. The share price rose more strongly than this, climbing 17 pe... |
| 14.04.2020 | HBM Healthcare Investments and HBM Partners donate protective equipment for emergency hospitals in Switzerland | HBM Healthcare Investments and HBM Partners are making a small but important contribution to the management of the COVID-19 pandemic in Switzerland. Through contacts with the leading Chinese online pharmacy Jianke Pharmaceutical (www.jianke... |
| 08.04.2020 | HBM portfolio company Arrakis Therapeutics enters strategic collaboration and license agreement with Roche | Arrakis Therapeutics, a privately held company in the portfolio of HBM Healthcare Investments, today announced a strategic collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery of RNA-targeted small m... |
| 01.04.2020 | HBM Healthcare Investments expects net profit of more than CHF 180 million for the financial year ending 31 March 2020; net asset value per share (NAV) increased by 14 percent; share price rose by 17 ... | HBM Healthcare Investments closes the 2019/2020 financial year with an excellent result despite the severe market turbulence in recent weeks. The net asset value per share (NAV) increased by 13.9 percent to CHF 208.25. The share price rose ... |
| 03.02.2020 | Successful IPO for the HBM portfolio company Arcutis Biotherapeutics | Arcutis Biotherapeutics (Nasdaq: ARQT), a privately held company in the portfolio of HBM Healthcare Investments, successfully went public last Friday. Due to the high demand, the company increased the number of newly issued shares by around... |
| 24.01.2020 | HBM Healthcare Investments Quarterly Report December 2019 | In the third quarter of the 2019/2020 financial year, HBM Healthcare Investments achieved a net profit of CHF 163.2 million. As a result, for the first nine months of the 2019/2020 financial year, net profit rose to CHF 265.7 million, with ... |
| 03.01.2020 | HBM Healthcare Investments achieves high value growth in calendar year 2019: Net asset value per share (NAV) +33%, share price +48% | HBM Healthcare Investments benefited from its well developing investments in private and public companies and achieved a high value increase in a friendly market environment in calendar year 2019: The net asset value per share (NAV) rose by... |
| 25.10.2019 | HBM Healthcare Investments Half-Year Report September 2019 | HBM Healthcare Investments continued successfully in the second quarter of the 2019/2020 financial year. A quarterly profit of CHF 27 million took the Company's overall first-half result to CHF 102 million. Net asset value rose by 7.8 perce... |
| 04.10.2019 | IPO of Viela Bio lifts net asset value per HBM-share by CHF 1.40 (+0.7%) | Viela Bio (Nasdaq: VIE), a privately held company in the portfolio of HBM Healthcare Investments, successfully went public. The company raised USD 150 million through the issuance of 7.9 million new shares at a price of USD 19.00 per share.... |
| 01.10.2019 | Key Figures | |
| 16.09.2019 | Successful stock market debut of SpringWorks Therapeutics increases net asset value per HBM- share by CHF 2.11 (+1.1%) | SpringWorks Therapeutics (Nasdaq: SWTX), a privately held company in the portfolio of HBM Healthcare Investments, successfully went public last Friday. The company placed 9 million new shares at USD 18.00 per share, raising a total of USD 1... |
| 22.07.2019 | HBM Healthcare Investments Quarterly Report June 2019 | HBM Healthcare Investments had a successful start to the new 2019/2020 financial year, with net asset value (NAV) per share rising by 5.7 percent to CHF 200.29 during the first quarter. The share price increased by 8.9 percent to CHF 183.80... |
| 26.06.2019 | HBM Healthcare Investments launches new share buy-back programme | At the Annual General Meeting of HBM Healthcare Investments AG on 24 June 2019, the shareholders approved a new share buy-back programme for a maximum of 696'000 shares (10% of the shares issued) for the purpose of cancellation by means of ... |
| 24.06.2019 | Shareholders' Meeting of HBM Healthcare Invest-ments approved all proposals by the Board of Directors | At today's ordinary Shareholder's Meeting of HBM Healthcare Investments Ltd the Shareholders approved all proposals submitted by the Board of Directors. A total of about 42% of all shares were represented at the Shareholders' Meeting. |